Funding This work was funded by NIH R61NS112441, R01 NS100090, R01 ES026892, R21 AG062378, and R01 EB026533
Injectable routes (subcutaneous, intramuscular, local endometrial injection) give precise dosing but carry risks of local trauma, infection, and systemic spillover
10 mg equals 10,000 mcg 10,000 mcg / 2 mL = 5,000 mcg per mL 2,500 mcg / 5,000 mcg per mL = 0.5 mL Tirzepatide 10 mg vial with 2 mL example A 10 mg tirzepatide vial mixed with 2 mL gives 5 mg/mL, or 5,000 mcg/mL
Thus, DN30 with dual effects on c-Met and HGF separately can inhibit the c-Met/HGF pathway [173]
Injecting contaminated solutions can cause infections ranging from mild injection site reactions to serious systemic infections
When introduced systemically, it travels through your bloodstream, instructing your fibroblasts (the cells that make collagen) to get back to work